{
    "filename": "pdf.pdf",
    "content_type": "application/pdf",
    "file_size": 33405,
    "metadata": {
        "identifiers": {
            "doi": "10.1016/s0140-6736(20)30371-8",
            "arxiv": null,
            "isbn": null,
            "doc_id": null,
            "url": "http://www.thelancet.com/article/S0140673620303718/pdf"
        },
        "title": "Full spectrum of COVID-19 severity still being depicted \u2013 Authors' reply",
        "author": "Xiaoying Gu, Bin Cao, Jianwei Wang",
        "date": 2020,
        "affiliations": [
            "Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS 2018-I2M-1-003), National Science Grant for Distinguished Young Scholars (81425001/H0104), the National Key Research and Development Program of China (2018YFC1200102), and The Beijing Science and Technology Project (Z19110700660000)."
        ],
        "journal": "The Lancet",
        "abstract": "Zhou Xu and colleagues point out that mortality, which should be referred correctly and more clearly as case fatality ratio, among the first 41 cases with laboratory-confirmed 2019 novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was misleading in our Article.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>]",
        "references": "@incollection{huang-a,\n  author = {Huang, C. and Wang, Y. and Li, X.},\n  title = {Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China},\n  source = {Lancet 2020; published online},\n  date = {Jan},\n  volume = {24},\n  url = {https://doi.org/10.1016/S0140-6736},\n  more-authors = {true},\n  language = {}\n}\n@incollection{wang-a,\n  author = {Wang, C. and Horby, P.W. and Hayden, F.G. and Gao, G.F.},\n  title = {A novel coronavirus outbreak of global health concern},\n  source = {Lancet 2020; published online},\n  date = {Jan},\n  volume = {24},\n  url = {https://doi.org/10.1016/S0140-6736},\n  language = {}\n}\n@techreport{unknown-a,\n  title = {Notice on the issuance of diagnosis and treatment procedure for pneumonia patients infected with the 2019-nCoV},\n  date = {(version 5). Feb},\n  volume = {5},\n  url = {http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204},\n  number = {2020},\n  language = {},\n  urldate = {a79db5b8912d4440.shtml (Feb 7, 2020).},\n  institution = {China National Health Commission}\n}\n@misc{unknown-b,\n  title = {US National Library of Medicine-ClinicalTrials. gov. Mild/Moderate 2019-nCoV Remdesivir RCT. Feb 5, 2020},\n  url = {https://clinicaltrials.gov/ct2/show/NCT04252664},\n  language = {},\n  urldate = {(Feb 7, 2020).}\n}\n@misc{unknown-c,\n  title = {US National Library of Medicine-ClinicalTrials. gov. Severe 2019-nCoV Remdesivir RCT},\n  url = {https://clinicaltrials.gov/ct2/show/NCT04257656},\n  unmatched-accessed = {(accessed Feb 7, 2020).},\n  language = {},\n  urldate = {Feb 6, 2020.}\n}\n",
        "links": [
            "http://ees.elsevier.com/",
            "http://www.thelancet.com",
            "https://doi.org/10.1016/"
        ],
        "emails": [
            "caobin_ben@163.com"
        ],
        "references_ris": "TY  - CHAP\nAU  - Huang, C.\nAU  - Wang, Y.\nAU  - Li, X.\nTI  - Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China\nT2  - Lancet 2020; published online\nPY  - Jan\nDA  - Jan\nVL  - 24\nUR  - https://doi.org/10.1016/S0140-6736\nC1  - true\nLA  - \nER  - \n\nTY  - CHAP\nAU  - Wang, C.\nAU  - Horby, P.W.\nAU  - Hayden, F.G.\nAU  - Gao, G.F.\nTI  - A novel coronavirus outbreak of global health concern\nT2  - Lancet 2020; published online\nPY  - Jan\nDA  - Jan\nVL  - 24\nUR  - https://doi.org/10.1016/S0140-6736\nLA  - \nER  - \n\nTY  - RPRT\nTI  - Notice on the issuance of diagnosis and treatment procedure for pneumonia patients infected with the 2019-nCoV\nPY  - (version 5). Feb\nDA  - (version 5). Feb\nVL  - 5\nUR  - http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204\nIS  - 2020\nLA  - \nC1  - a79db5b8912d4440.shtml (Feb 7, 2020).\nC1  - China National Health Commission\nER  - \n\nTY  - GEN\nTI  - US National Library of Medicine-ClinicalTrials. gov. Mild/Moderate 2019-nCoV Remdesivir RCT. Feb 5, 2020\nUR  - https://clinicaltrials.gov/ct2/show/NCT04252664\nLA  - \nC1  - (Feb 7, 2020).\nER  - \n\nTY  - GEN\nTI  - US National Library of Medicine-ClinicalTrials. gov. Severe 2019-nCoV Remdesivir RCT\nUR  - https://clinicaltrials.gov/ct2/show/NCT04257656\nC1  - (accessed Feb 7, 2020).\nLA  - \nC1  - Feb 6, 2020.\nER  - \n\n",
        "author_conclusions": [],
        "table_captions": [],
        "figure_captions": []
    },
    "sections": {
        "limitations": [
            "Without denying the limitations of our study[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] at the time of publication, we still hope our results provided a useful depiction of clinical features of SARS-CoV-2 infection at the very early stage of the outbreak and during progression of disease."
        ],
        "introduction": [
            "Zhou Xu and colleagues point out that mortality, which should be referred correctly and more clearly as case fatality ratio, among the first 41 cases with laboratory-confirmed 2019 novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was misleading in our Article.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>]",
            "We definitely agree that the case fatality ratio among the first 41 cases cannot represent the case fatality ratio of the full disease spectrum during the outbreak of COVID-19. From the perspective of case detection, the reasons for the inconsistency between the case fatality ratio reported in our Article[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] and data that have become available since publication of our Article[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] were clearly clarified in advance in the comment by Chen Wang and colleagues.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>] Patients with the most severe symptoms were paid attention to during the early stages of the outbreak because of limited resources to detect severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infection. From the perspective of treatment, even the most up-to-date case fatality ratio is expected to decrease as diagnosis and treatment procedure for patients with pneumonia who are infected with SARS-CoV-2 is improving,[<a class=\"ref-link\" id=\"c3\" href=\"#r3\">3</a>] potential drugs to treat COVID-19 are being evaluated for efficacy and safety in ongoing clinical trials,[<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>,<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>] and management is becoming more intense, not only for patients with severe infection but also for those with moderate, mild, or even asymptomatic infection."
        ]
    },
    "structured_content": {},
    "participants": [
        {
            "participant": "cases with laboratory-confirmed 2019 novel coronavirus disease",
            "number": 41,
            "context": ". <mark class=\"stats\">Zhou Xu and colleagues point out that mortality, which should be referred correctly and more clearly as case fatality ratio, among the first 41 cases with laboratory-confirmed 2019 novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was misleading in our Article.1</mark>. "
        },
        {
            "participant": "cases with laboratory-confirmed 2019 novel coronavirus disease",
            "number": 41,
            "context": "COVID-19 severity still being depicted. <mark class=\"stats\">Zhou Xu and colleagues point out that mortality, which should be referred correctly and more clearly as case fatality ratio, among the first 41 cases with laboratory-confirmed 2019 novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was misleading in our Article.1</mark>. We definitely agree that the case fatality ratio among the first 41 cases cannot represent the case fatality ratio of the full disease spectrum during the outbreak of COVID-19"
        },
        {
            "participant": "cases",
            "number": 41,
            "context": "Zhou Xu and colleagues point out that mortality, which should be referred correctly and more clearly as case fatality ratio, among the first 41 cases with laboratory-confirmed 2019 novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was misleading in our Article.1. <mark class=\"stats\">We definitely agree that the case fatality ratio among the first 41 cases cannot represent the case fatality ratio of the full disease spectrum during the outbreak of COVID-19</mark>. From the perspective of case detection, the reasons for the inconsistency between the case fatality ratio reported in our Article[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] and data that have become available since publication of our Article[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] were clearly clarified in advance in the comment by Chen Wang and colleagues.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>]"
        }
    ],
    "statistics": [],
    "keywords": [
        "coronavirus",
        "article[<a class=\"ref link",
        "case fatality ratio",
        "pneumonia",
        "sars cov",
        "treatment procedure",
        "Chinese Academy of Medical Sciences",
        "COVID-19",
        "novel coronavirus disease",
        "zhou xu",
        "us national library",
        "remdesivir"
    ],
    "keyword_relevance": {
        "case fatality ratio": 0.23809523809523808,
        "COVID-19": 0.23809523809523808,
        "coronavirus": 0.14285714285714285,
        "Chinese Academy of Medical Sciences": 0.14285714285714285,
        "pneumonia": 0.09523809523809523,
        "treatment procedure": 0.09523809523809523,
        "novel coronavirus disease": 0.047619047619047616,
        "article[<a class=\"ref link": 0.0,
        "sars cov": 0.0,
        "zhou xu": 0.0,
        "us national library": 0.0,
        "remdesivir": 0.0
    },
    "species": [],
    "summary": [
        "Zhou Xu and colleagues point out that mortality, which should be referred correctly and more clearly as case fatality ratio, among the first 41 cases with laboratory-confirmed 2019 novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was misleading in the Article.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>].",
        "Full spectrum of",
        "COVID-19 severity still being depicted",
        "The authors definitely agree that the case fatality ratio among the first 41 cases cannot represent the case fatality ratio of the full disease spectrum during the outbreak of COVID-19.",
        "From the perspective of case detection, the reasons for the inconsistency between the case fatality ratio reported in the Article[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] and data that have become available since publication of the Article[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] were clearly clarified in advance in the comment by Chen Wang and colleagues.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>] Patients with the most severe symptoms were paid attention to during the early stages of the outbreak because of limited resources to detect severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infection.",
        "From the perspective of treatment, even the most up-to-date case fatality ratio is expected to decrease as diagnosis and treatment procedure for patients with pneumonia who are infected with SARS-CoV-2 is improving,[<a class=\"ref-link\" id=\"c3\" href=\"#r3\">3</a>] potential drugs to treat COVID-19 are being evaluated for efficacy and safety in ongoing clinical trials,[<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>,<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>] and management is becoming more intense, not only for patients with severe infection but for those with moderate, mild, or even asymptomatic infection.",
        "Without denying the limitations of the study[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] at the time of publication, the authors still hope the results provided a useful depiction of clinical features of SARS-CoV-2 infection at the very early stage of the outbreak and during progression of disease.",
        "Intense and continuous efforts are needed for medical workers and researchers all over the world to get the full picture of the spectrum of disease severity of COVID-19 and to overcome the huge health challenge.",
        "The authors declare funding by the Special Project for Emergency of the Ministry of Science and Technology (2020YFC0841300), Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS 2018-I2M-1-003), National Science Grant for Distinguished Young Scholars (81425001/H0104), the National Key Research and Development Program of China (2018YFC1200102), and The Beijing Science and Technology Project (Z19110700660000).",
        "Xiaoying Gu, *Bin Cao, Jianwei Wang caobin_ben@163.com",
        "Www.thelancet.com Published online February 14, 2020 https://doi.org/10.1016/S0140-6736(20)30371-8",
        "Published Online February 14, 2020 https://doi.org/10.1016/ S0140-6736(20)30371-8",
        "Submissions should be made via the electronic submission system at http://ees.elsevier.com/ thelancet/"
    ],
    "structured_summary": {
        "Introduction": [
            "Zhou Xu and colleagues point out that mortality, which should be referred correctly and more clearly as case fatality ratio, among the first 41 cases with laboratory-confirmed 2019 novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was misleading in the Article.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>].",
            "Full spectrum of",
            "COVID-19 severity still being depicted"
        ],
        "Results": [
            "The authors definitely agree that the case fatality ratio among the first 41 cases cannot represent the case fatality ratio of the full disease spectrum during the outbreak of COVID-19.",
            "From the perspective of case detection, the reasons for the inconsistency between the case fatality ratio reported in the Article[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] and data that have become available since publication of the Article[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] were clearly clarified in advance in the comment by Chen Wang and colleagues.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>] Patients with the most severe symptoms were paid attention to during the early stages of the outbreak because of limited resources to detect severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infection.",
            "From the perspective of treatment, even the most up-to-date case fatality ratio is expected to decrease as diagnosis and treatment procedure for patients with pneumonia who are infected with SARS-CoV-2 is improving,[<a class=\"ref-link\" id=\"c3\" href=\"#r3\">3</a>] potential drugs to treat COVID-19 are being evaluated for efficacy and safety in ongoing clinical trials,[<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>,<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>] and management is becoming more intense, not only for patients with severe infection but for those with moderate, mild, or even asymptomatic infection.",
            "Without denying the limitations of the study[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] at the time of publication, the authors still hope the results provided a useful depiction of clinical features of SARS-CoV-2 infection at the very early stage of the outbreak and during progression of disease.",
            "Intense and continuous efforts are needed for medical workers and researchers all over the world to get the full picture of the spectrum of disease severity of COVID-19 and to overcome the huge health challenge.",
            "The authors declare funding by the Special Project for Emergency of the Ministry of Science and Technology (2020YFC0841300), Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS 2018-I2M-1-003), National Science Grant for Distinguished Young Scholars (81425001/H0104), the National Key Research and Development Program of China (2018YFC1200102), and The Beijing Science and Technology Project (Z19110700660000).",
            "Xiaoying Gu, *Bin Cao, Jianwei Wang caobin_ben@163.com"
        ],
        "Conclusion": [
            "Www.thelancet.com Published online February 14, 2020 https://doi.org/10.1016/S0140-6736(20)30371-8",
            "Published Online February 14, 2020 https://doi.org/10.1016/ S0140-6736(20)30371-8",
            "Submissions should be made via the electronic submission system at http://ees.elsevier.com/ thelancet/"
        ]
    },
    "reference_links": [
        {
            "id": "1",
            "alt_id": "Huang_et+al_Jan_a",
            "entry": "1 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; published online Jan 24. https://doi.org/10.1016/ S0140-6736(20)30183-5.",
            "url": "https://doi.org/10.1016/S0140-6736(20)30183-5",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Huang%20C%20Wang%20Y%20Li%20X%20et%20al%20Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan%20China%20Lancet%202020%20published%20online%20Jan%2024%20httpsdoiorg101016%20S0140673620301835",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Huang%20C%20Wang%20Y%20Li%20X%20et%20al%20Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan%20China%20Lancet%202020%20published%20online%20Jan%2024%20httpsdoiorg101016%20S0140673620301835"
        },
        {
            "id": "2",
            "alt_id": "Wang_et+al_Jan_a",
            "entry": "2 Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020; published online Jan 24. https://doi.org/10.1016/S0140-6736(20)30185-9.",
            "crossref": "https://dx.doi.org/10.1016/S0140-6736(20)30185-9",
            "scite": "https://scite.ai/reports/10.1016/S0140-6736(20)30185-9",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/S0140-6736%2820%2930185-9"
        },
        {
            "id": "3",
            "alt_id": "3_(version 5). Feb_a",
            "entry": "3 China National Health Commission. Notice on the issuance of diagnosis and treatment procedure for pneumonia patients infected with the 2019-nCoV (version 5). Feb 5, 2020. http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204 a79db5b8912d4440.shtml (accessed Feb 7, 2020).",
            "url": "http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204"
        },
        {
            "id": "4",
            "alt_id": "4_2019_b",
            "entry": "4 US National Library of Medicine-ClinicalTrials. gov. Mild/Moderate 2019-nCoV Remdesivir RCT. Feb 5, 2020. https://clinicaltrials.gov/ct2/show/NCT04252664?term=bin+cao&draw=2&rank=10 (accessed Feb 7, 2020).",
            "url": "https://clinicaltrials.gov/ct2/show/NCT04252664?term=bin+cao&draw=2&rank=10"
        },
        {
            "id": "5",
            "alt_id": "5_2019_c",
            "entry": "5 US National Library of Medicine-ClinicalTrials. gov. Severe 2019-nCoV Remdesivir RCT. Feb 6, 2020. https://clinicaltrials.gov/ct2/show/NCT04257656?term=bin+cao&draw=2&rank=4 (accessed Feb 7, 2020).",
            "url": "https://clinicaltrials.gov/ct2/show/NCT04257656?term=bin+cao&draw=2&rank=4"
        }
    ],
    "facts": [
        "2019 novel coronavirus disease was misleading in our Article.1",
        "2019 novel coronavirus disease was misleading in our Article.[1",
        "the reasons for the inconsistency between the case fatality ratio reported in our Article[1",
        "data that have become available since publication of our Article[1",
        "most up-to-date case fatality ratio is expected to decrease as diagnosis and treatment procedure for patients",
        "with pneumonia who are infected with SARS-CoV-2 is improving,[3] potential drugs to treat COVID-19 are being evaluated for efficacy",
        "still hope our results provided a useful depiction of clinical features of SARS-CoV-2 infection",
        "continuous efforts are needed for medical workers and researchers",
        "all over the world to get the full picture of the spectrum of disease severity",
        "Submissions should be made via our electronic submission system at http://ees.elsevier.com/ thelancet/"
    ],
    "claims": [
        "Without denying the limitations of our study1 at the time of publication, we still hope our results provided a useful depiction of clinical features of SARS-CoV-2 infection at the very early stage of the outbreak and during progression of disease"
    ],
    "findings": [],
    "processes": [],
    "key_statements": [
        "From the perspective of treatment, even the most up-to-date case fatality ratio is expected to decrease as diagnosis and treatment procedure for patients with pneumonia who are infected with SARS-CoV-2 is improving,[<a class=\"ref-link\" id=\"c3\" href=\"#r3\">3</a>] potential drugs to treat COVID-19 are being evaluated for efficacy and safety in ongoing clinical trials,[<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>,<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>] and management is becoming more intense, not only for patients with severe infection but for those with moderate, mild, or even asymptomatic infection",
        "Intense and continuous efforts are needed for medical workers and researchers all over the world to get the full picture of the spectrum of disease severity of COVID-19 and to overcome the huge health challenge"
    ],
    "top_statements": [
        "Zhou Xu and colleagues point out that mortality, which should be referred correctly and more clearly as case fatality ratio, among the first 41 cases with laboratory-confirmed 2019 novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was misleading in our Article.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>]",
        "From the perspective of treatment, even the most up-to-date case fatality ratio is expected to decrease as diagnosis and treatment procedure for patients with pneumonia who are infected with SARS-CoV-2 is improving,[<a class=\"ref-link\" id=\"c3\" href=\"#r3\">3</a>] potential drugs to treat COVID-19 are being evaluated for efficacy and safety in ongoing clinical trials,[<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>,<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>] and management is becoming more intense, not only for patients with severe infection but for those with moderate, mild, or even asymptomatic infection",
        "Intense and continuous efforts are needed for medical workers and researchers all over the world to get the full picture of the spectrum of disease severity of COVID-19 and to overcome the huge health challenge"
    ],
    "headline": "From the perspective of treatment, even the most up-to-date case fatality ratio is expected to decrease as diagnosis and treatment procedure for patients with pneumonia who are infected with SARS-CoV-2 is improving,3 potential drugs to treat COVID-19 are being evaluated for efficacy and safety in ongoing clinical trials,4,5 and management is becoming more intense, not only for patients with severe infection but for those with moderate, mild, or even asymptomatic infection",
    "contexts": [],
    "abbreviations": {
        "CAMS": "Chinese Academy of Medical Sciences"
    }
}
